Cytokinetics Reports Added Safety, Pharmacodynamic Results from ATOMIC-AHF Study

Cytokinetics, Incorporated (NASDAQ: CYTK ) today announced the presentation of additional data from the ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) clinical trial at a Late Breaking Clinical Trials Session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Orlando,